JAMA Dermatology

@jamadermatology.com

158 Followers 62 Following

JAMA Dermatology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications. 🌐 JAMADermatology.com

JAMA Dermatology article, "Commercial Price Variation for Common Dermatologic Procedures." Authors: Chelsea Deitelzweig, Ravi Dhawan, Kyle King, et al. Published Online: June 17, 2026. Includes links for author affiliations and article information.
Clinical image showing pale skin of an axilla, featuring dark hair and numerous scattered small, reddish, raised pruritic papules, consistent with poultry red mite bites.
A JAMA Dermatology research letter titled 'GLP-1 Receptor Agonist Use and Clinical Outcomes in Patients With Hidradenitis Suppurativa' by B. Jastrząb-Miśkiewicz, J.C. Szepietowski, and P.K. Krajewski. Published online July 1, 2026.
Table 3: Core Outcome Set Items. This table presents outcomes, their definitions, and final vote percentages for inclusion. Top items (97% include) are Treatment duration, adverse events, & patient satisfaction. Lowest (86% include) is Overall assessment of focused area.
Immunohistochemistry for CD4, original magnification × 100: Dense, diffuse reddish-brown stained cells are visible in the lower tissue area. Immunohistochemistry for CD8, original magnification × 100: Reddish-brown cells form a concentrated band at the top, with scattered cells below.
Volcano Plot & Bar Chart: Differentially Expressed Proteins in Rosacea. Plot A shows gene fold change vs. p-value; orange dots up, blue down. Plot B lists downregulated GO terms (Metabolism, Hormone, Immune, Neural) with tRNA metabolic process being most significant.
Volcano Plot & Bar Chart: Differentially Expressed Proteins in Rosacea. Plot A shows gene fold change vs. p-value; orange dots up, blue down. Plot B lists downregulated GO terms (Metabolism, Hormone, Immune, Neural) with tRNA metabolic process being most significant.
Table 3: Core Outcome Set Items. This table presents outcomes, their definitions, and final vote percentages for inclusion. Top items (97% include) are Treatment duration, adverse events, & patient satisfaction. Lowest (86% include) is Overall assessment of focused area.
Immunohistochemistry for CD4, original magnification × 100: Dense, diffuse reddish-brown stained cells are visible in the lower tissue area. Immunohistochemistry for CD8, original magnification × 100: Reddish-brown cells form a concentrated band at the top, with scattered cells below.
JAMA Dermatology Research Letter: "GLP-1 Receptor Agonist Use and Clinical Outcomes in Patients With Hidradenitis Suppurativa." Authors: Beata Jastrząb-Miśkiewicz, Jacek C. Szepietowski, Piotr K. Krajewski. Published Online: July 1, 2026.
Screenshot of a JAMA Dermatology article: 'Topical Preparations for Moderate to Severe Rosacea Treatment: A Systematic Review and Network Meta-Analysis.' Authored by Amstutz et al., published online July 1, 2026, with DOI: 10.1001/jamadermatol.2026.2062.
Immunohistochemistry for CD4, original magnification × 100: Dense, diffuse reddish-brown stained cells are visible in the lower tissue area. Immunohistochemistry for CD8, original magnification × 100: Reddish-brown cells form a concentrated band at the top, with scattered cells below.
Table 3: Core Outcome Set Items. This table presents outcomes, their definitions, and final vote percentages for inclusion. Top items (97% include) are Treatment duration, adverse events, & patient satisfaction. Lowest (86% include) is Overall assessment of focused area.
Volcano Plot & Bar Chart: Differentially Expressed Proteins in Rosacea. Plot A shows gene fold change vs. p-value; orange dots up, blue down. Plot B lists downregulated GO terms (Metabolism, Hormone, Immune, Neural) with tRNA metabolic process being most significant.
JAMA Dermatology article page. Editorial title: "The Challenge of Defining Atopic Dermatitis Remission" by Hywel Charles Williams, DSc. Published Online: April 15, 2026, in JAMA Dermatol, 2026;162;(6):555-556. Includes DOI & navigation links.
JAMA Dermatology article titled 'Progression From Acute to Chronic Urticaria: A Systematic Review'. Authored by Enrique Gómez de la Fuente, Francisco Javier Ortiz de Frutos, Noelia Álvarez-Díaz, et al. Published online June 24, 2026.
Diagram of longitudinal study designs for Denmark and England cohorts. Timelines from birth show various assessment windows for inclusion, exposure (AD diagnosis), covariates (demographics, comorbidities), and exclusion. Data observability is indicated by color, leading to follow-up periods ending at age 18 (Denmark) and 11.5 (England).
JAMA Dermatology journal article titled "Diagnostic Modalities and Nodal Staging in High-Risk Cutaneous Squamous Cell Carcinoma." Authored by Carla Ferrándiz-Pulido, Álvaro Gómez-Tomás, Sahyly Siurana et al. Published online April 22, 2026.
JAMA Dermatology article, "Commercial Price Variation for Common Dermatologic Procedures." Authors: Chelsea Deitelzweig, Ravi Dhawan, Kyle King, et al. Published Online: June 17, 2026. Includes links for author affiliations and article information.
Clinical image showing pale skin of an axilla, featuring dark hair and numerous scattered small, reddish, raised pruritic papules, consistent with poultry red mite bites.
Immunohistochemistry for CD4, original magnification × 100: Dense, diffuse reddish-brown stained cells are visible in the lower tissue area. Immunohistochemistry for CD8, original magnification × 100: Reddish-brown cells form a concentrated band at the top, with scattered cells below.
Table 3: Core Outcome Set Items. This table presents outcomes, their definitions, and final vote percentages for inclusion. Top items (97% include) are Treatment duration, adverse events, & patient satisfaction. Lowest (86% include) is Overall assessment of focused area.
Volcano Plot & Bar Chart: Differentially Expressed Proteins in Rosacea. Plot A shows gene fold change vs. p-value; orange dots up, blue down. Plot B lists downregulated GO terms (Metabolism, Hormone, Immune, Neural) with tRNA metabolic process being most significant.
Figure. Histogram of Probabilistic Sensitivity Analysis. The Y-axis shows 'KC events, No.', X-axis 'Differential cost per QALY gained, $'. Distribution is skewed left, peaking near -70,000 to -80,000 at ~680 events, with a dotted line marking the central tendency. Range: -300,000 to 0.
Figure 1: Two line graphs show age-standardized melanoma mortality rates per 100,000 from 2009-2022. Graph A displays German regions (e.g., Bavaria), generally showing rates between 1-2. Graph B shows non-German regions (e.g., Denmark) with varying rates, some higher.
Figure. Histogram of Probabilistic Sensitivity Analysis. X-axis: Differential cost per QALY gained, $ (-300,000 to 0). Y-axis: KC events, No. (0-800). The data is left-skewed, peaking around -75,000, with a dotted line near the peak.
Figure 1: Two line graphs of age-standardized melanoma mortality rates (per 100,000) from 2009-2022. Graph A, 'German regions,' shows 16 regions fluctuating 1-2. Graph B, 'Non-German regions,' shows 9 countries, with Denmark consistently higher.
Histogram of Probabilistic Sensitivity Analysis. The x-axis shows "Differential cost per QALY gained, $" from -300,000 to 0. The y-axis shows "KC events, No." The distribution is left-skewed, peaking between -100,000 and 0, with a dotted vertical line near the peak.
JAMA Dermatology case: 'An Adolescent With Waxy Mucocutaneous Lesions.' Two images show a clinical photograph of a tongue with waxy nodules & cobblestone-like appearance, and a hematoxylin-eosin stained tissue sample with hyalinized material (100µm scale). 'WHAT IS YOUR DIAGNOSIS?' quiz.
Line graphs titled "Age-Standardized Melanoma Mortality Rates (World Standard)". Graph A shows 16 German regions' rates from 2009-2022, generally between 1-2.5 per 100,000. Graph B shows 10 non-German regions' rates for the same period, ranging from 0.5-2.8.
Table 2: Median wait days for new patient dermatology appointments. General dermatologists (26-53 days median wait) have shorter wait times than pediatric dermatologists (49-89 days) for conditions like infantile hemangioma, atopic dermatitis, and acne. Absolute differences are significant (P <.001).
JAMA Dermatology Research Letter: Golimumab in Treatment-Refractory Hidradenitis Suppurativa by Madeline Sage, BS; Christopher J. Sayed, MD. Published Online: June 10, 2026. doi: 10.1001/jamadermatol.2026.1457
JAMA Dermatology Research Letter: 'Hidradenitis Suppurativa and Risk of Self-Harm and Suicide' by Nikolaj Holgersen et al. Published online as JAMA Dermatol on March 11, 2026. DOI: 10.1001/jamadermatol.2026.0037.
Histogram of KC events vs. Differential cost per QALY gained ($). Y-axis shows 0-800 KC events; X-axis -300,000 to 0. The data is left-skewed, peaking around -40,000 to -50,000 with approximately 650 events, marked by a dotted vertical line.
Figure 1. Two line graphs show age-standardized melanoma mortality rates per 100,000 from 2009-2022. Graph A displays data for 16 German regions, with rates mostly between 1-2.5. Graph B shows data for 9 non-German regions, with similar fluctuating rates.
Figure 1. Clinical Image of Melanoma Arising in a BAP1-Inactivated Melanocytic Tumor. A close-up of light-toned skin shows multiple small moles and one raised, reddish-brown lesion with a black arrow pointing to it. The area around this lesion appears red and inflamed.
Side-by-side comparison: Before treatment (A), a dark, raised lesion is on the philtrum above the upper lip. After treatment (B), the lesion is gone, leaving a faint healed area. Lips are red-brown.
Figure 1. Clinical Image of Both Legs. Bilateral lower legs show numerous, well-circumscribed atrophic yellow-brown plaques with mild peripheral scale.
Clinical image of skin with multiple moles. A prominent, raised, reddish-brown lesion with an irregular border is central, highlighted by a black arrow. The image title reads: 'Figure 1. Clinical Image of Melanoma Arising in a BAP1-Inactivated Melanocytic Tumor'.
Side-by-side comparison: Before treatment (A), a dark, raised lesion is on the philtrum above the upper lip. After treatment (B), the lesion is gone, leaving a faint healed area. Lips are red-brown.
Evidence Profile: 160 randomized clinical trials, 57,611 patients, 2000-2024. Sex: 32.8% Female, 67.2% Male. Age range 27-61. Studies mostly from hospitals worldwide. Comparisons involved systemic treatments vs placebo. Primary outcomes: PASI 90, serious adverse events.
JAMA Dermatology Research Letter: Risk of Immunologic Reactions During Monthly Therapy for Hansen Disease. Authors: Peyton V. Warp, Minsoo Kim, Kimberly Williams et al. Published Online: June 3, 2026. DOI: 10.1001/jamadermatol.2026.1262
A JAMA Dermatology webpage shows an Editorial: 'Human Genome Promise—Are We There Yet?' authored by Soo Hyun Kim, Shelley McCormick, and Hensin Tsao. Published online May 27, 2026. DOI: 10.1001/jamadermatol.2026.1303. Links for author affiliations and article information are also visible.
Kaplan-Meier curves: time to invasive cutaneous melanoma diagnosis for CDKN2A and MITF E318K variants vs. controls in UKBB and GMC cohorts. All variant groups show significantly higher cumulative melanoma incidence with age than controls, confirmed by low P-values.
JAMA Dermatology Brief Report: Neoadjuvant Capecitabine in Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck. Authors: Savanah Haidar, Alex Mlynarek, Philippe Lefrancois et al. Published Online: May 27, 2026. DOI: 10.1001/jamadermatol.2026.1331.
Figure 2. Algorithm for Clinical Risk Scoring System. Clinical symptoms: Hoarseness (+2 Points), Dysphagia (+4 Points). Disease severity (PDAI >18): Male patients (+2 Points, Max 8), Female patients (+1 Point, Max 7). Risk interpretation: Low (0-1 pts, <10% Prob, Routine monitoring); Intermediate (2-3 pts, 15-35% Prob, Frequent assessment); High (≥4 pts, >40% Prob, Prioritize laryngoscopy).
Figure 1: Cumulative incidence curve for skin cancer risk over 10 years. Patients with CLL (blue line) show a significantly higher risk (up to ~13%) compared to Controls (orange line, up to ~7%). ARD is 6.6 pp (95% CI, 5.7-7.4 pp; P<.001). A table below shows numbers at risk for both groups over time.
Figure 4: Box plots and ROC curves show AI (orange) and Dermatologists (dark grey) performance. AI generally has higher accuracy, balanced accuracy, and sensitivity, while Dermatologists show higher specificity. The ROC curve indicates overall superior AI performance.
Split image: (A) a right thigh with red, inflamed patches and smaller red bumps; "Clinical image of right anterior thigh". (B) a Hematoxylin-eosin stain(original magnification ×40) showing skin layers and tissue.
An excerpt from JAMA Dermatology - The Year in Review, 2025 by Kanade Shinkai, MD, PhD, presents JAMA Dermatology statistics for 2025 in a table. It includes manuscript data, information dissemination data, and top articles by views/downloads.
JAMA Dermatology infographic: RCT: Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity. Population: 151 Male, 123 Female. Intervention: 274 patients. Findings: Ixekizumab 5.8% vs. Ixekizumab + tirzepatide 27.1%.
Bar graphs show prediction analysis of future skin cancer burden based on the Bayesian Age-Period-Cohort Model, comparing observed, predicted, and global data for malignant melanoma, squamous cell carcinoma, and basal cell carcinoma.
Line graphs show adjusted mean adult height by cumulative isotretinoin dose in men/women. Graph A plots dose before conscription, B plots dose before age 15. Men's height is blue, women's is gold. Height increases slightly with dose in men.
A table titled "Association Between Genetically Defined Porokeratosis and Skin Cancer Outcomes." It presents data on subgroups, porokeratosis variant vs nonvariant prevalence, odds ratios, and p-values for KC, BCC, SCC, and Melanoma, stratified by AK status and age.
A JAMA Dermatology journal page titled "Targeting Cardiometabolic Disease to Improve Psoriasis-A New Treatment Paradigm Emerges" by Michael S. Garshick et al., published online May 15, 2026, doi: 10.1001/jamadermatol.2026.1694.
JAMA Dermatology RCT: Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity. Population: 151 Male, 123 Female. Intervention: 274 Patients randomized. Findings: 27.1% achieved PASI 100 with Ixekizumab + tirzepatide vs 5.8% with Ixekizumab.
Three images show a hand's progressive finger mobility after injections. A: Baseline (February 2025), fingers are tightly bent. B: After the first injection (March 2025), fingers are slightly straighter. C: After the second injection (April 2025), fingers are nearly straight.
Bar graphs show prediction analysis of future skin cancer burden based on the Bayesian Age-Period-Cohort Model, comparing observed, predicted, and global data for malignant melanoma, squamous cell carcinoma, and basal cell carcinoma.
The graphic outlines GLP-1 RA's effects on the body, showing increased insulin secretion in the pancreas, reduced hunger signals in the brain, decreased hepatic glucose production in the liver, delayed gastric emptying through POMC NPY, and reduced postprandial glucose in the stomach.
Clinical image shows cobblestoning monomorphic papules on lower extremities. Histopathological image reveals amorphous pink material. Text describes a case of a 62-year-old Vietnamese man with hepatitis B and a chronic rash. "WHAT IS YOUR DIAGNOSIS?"